- Home
- IBTA vs MIRM Comparison
IBTA vs MIRM Comparison
Compare IBTA & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- MIRM
- Stock Information
- Founded
- IBTA 2011
- MIRM 2018
- Country
- IBTA United States
- MIRM United States
- Employees
- IBTA N/A
- MIRM N/A
- Industry
- IBTA
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- IBTA
- MIRM Health Care
- Exchange
- IBTA Nasdaq
- MIRM Nasdaq
- Market Cap
- IBTA 2.2B
- MIRM 1.9B
- IPO Year
- IBTA 2024
- MIRM 2019
- Fundamental
- Price
- IBTA $67.99
- MIRM $42.00
- Analyst Decision
- IBTA Strong Buy
- MIRM Strong Buy
- Analyst Count
- IBTA 9
- MIRM 12
- Target Price
- IBTA $89.67
- MIRM $57.58
- AVG Volume (30 Days)
- IBTA 369.1K
- MIRM 356.2K
- Earning Date
- IBTA 11-13-2024
- MIRM 11-12-2024
- Dividend Yield
- IBTA N/A
- MIRM N/A
- EPS Growth
- IBTA N/A
- MIRM N/A
- EPS
- IBTA 0.48
- MIRM N/A
- Revenue
- IBTA $368,548,000.00
- MIRM $307,028,000.00
- Revenue This Year
- IBTA $18.80
- MIRM $82.14
- Revenue Next Year
- IBTA $16.65
- MIRM $26.18
- P/E Ratio
- IBTA $150.85
- MIRM N/A
- Revenue Growth
- IBTA 74.91
- MIRM 112.14
- 52 Week Low
- IBTA $41.87
- MIRM $23.14
- 52 Week High
- IBTA $110.95
- MIRM $48.89
- Technical
- Relative Strength Index (RSI)
- IBTA N/A
- MIRM 42.64
- Support Level
- IBTA N/A
- MIRM $41.58
- Resistance Level
- IBTA N/A
- MIRM $43.37
- Average True Range (ATR)
- IBTA 0.00
- MIRM 1.67
- MACD
- IBTA 0.00
- MIRM -0.48
- Stochastic Oscillator
- IBTA 0.00
- MIRM 7.05
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.